ResearcherPathologisches InstitutActive in the last 2 years
Michael Guenther
Matched on OpenAlex author ID A5109337993. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 39
2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 3 papers
Papers 12
- Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117035↗
- Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. First author DOI 10.1016/j.ejca.2026.117040↗
- Neutrophil-Driven Trogocytosis in Pancreatic Ductal Adenocarcinoma Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic P… Co-author DOI 10.1053/j.gastro.2026.04.021↗
- Intratumoral bacterial abundance confers poor response to adjuvant gemcitabine in resected pancreatic cancer patients which is mitigated by postoperative antib… Co-author DOI 10.1038/s41416-025-03078-2↗
- PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
- The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer. Co-author DOI 10.3390/biom15030426↗
- Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
- TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02295-x↗
- The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. Co-author DOI 10.1002/ijc.34044↗
- Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac039↗
- Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Co-author DOI 10.1038/s41416-020-01029-7↗
- POLE gene hotspot mutations in advanced pancreatic cancer. Co-author DOI 10.1007/s00432-018-2746-x↗
Closest collaborators
The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Steffen Ormanns · 12 shared papers, 2018–2026 · strength 2.31
- Paper Intratumoral bacterial abundance confers poor response to adjuvant gemcitabine in resected pancreatic cancer patients w… DOI 10.1038/s41416-025-03078-2↗
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtypi… DOI 10.3390/biom15030426↗
- Volker Heinemann · 9 shared papers, 2018–2026 · strength 1.57
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtypi… DOI 10.3390/biom15030426↗
- Paper The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. DOI 10.1002/ijc.34044↗
- Stefan Hubert Boeck · 9 shared papers, 2018–2026 · strength 1.57
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtypi… DOI 10.3390/biom15030426↗
- Paper The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. DOI 10.1002/ijc.34044↗
- Sai Agash Surendran · 5 shared papers, 2022–2026 · strength 1.18
- Paper Intratumoral bacterial abundance confers poor response to adjuvant gemcitabine in resected pancreatic cancer patients w… DOI 10.1038/s41416-025-03078-2↗
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtypi… DOI 10.3390/biom15030426↗
- Michael Haas · 6 shared papers, 2018–2025 · strength 0.95
- Paper The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtypi… DOI 10.3390/biom15030426↗
- Paper TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. DOI 10.1038/s41416-023-02295-x↗
- Paper PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. DOI 10.1038/s41586-025-09017-8↗
- Jens Werner · 4 shared papers, 2020–2023 · strength 0.62
- Paper The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. DOI 10.1002/ijc.34044↗
- Paper TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. DOI 10.1038/s41416-023-02295-x↗
- Paper Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. DOI 10.1093/jncics/pkac039↗
- Stephan Krüger · 4 shared papers, 2018–2025 · strength 0.51
- Paper PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. DOI 10.1038/s41586-025-09017-8↗
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Paper Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translationa… DOI 10.1038/s41416-020-01029-7↗
- Julia V. Mayerle · 3 shared papers, 2020–2026 · strength 0.46
- Paper Neutrophil-Driven Trogocytosis in Pancreatic Ductal Adenocarcinoma Liver Metastases Restrains Immunosuppressive Macroph… DOI 10.1053/j.gastro.2026.04.021↗
- Paper Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. DOI 10.1093/jncics/pkac039↗
- Paper Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translationa… DOI 10.1038/s41416-020-01029-7↗
- Danmei Zhang · 2 shared papers, 2023–2026 · strength 0.43
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Christoph Benedikt Westphalen · 3 shared papers, 2018–2023 · strength 0.33
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Paper Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translationa… DOI 10.1038/s41416-020-01029-7↗
- Paper POLE gene hotspot mutations in advanced pancreatic cancer. DOI 10.1007/s00432-018-2746-x↗
- Brigitte Kimmel · 1 shared paper, 2026 · strength 0.29
- Volker Kunzmann · 1 shared paper, 2026 · strength 0.29
- Anna Silvia Wenning · 1 shared paper, 2026 · strength 0.23
- Nic G. Reitsam · 1 shared paper, 2026 · strength 0.23
- Konstantin Bräutigam · 1 shared paper, 2026 · strength 0.23
- Martin Wartenberg · 1 shared paper, 2026 · strength 0.23
- Bruno Märkl · 1 shared paper, 2026 · strength 0.23
- Przemyslaw Grochowski · 1 shared paper, 2026 · strength 0.23
- Beat Gloor · 1 shared paper, 2026 · strength 0.23
- Robert Grützmann · 1 shared paper, 2026 · strength 0.23
- Christian P. Pilarsky · 1 shared paper, 2026 · strength 0.23
- Larissa Belz · 1 shared paper, 2026 · strength 0.21
- Stefanie Bärthel · 1 shared paper, 2026 · strength 0.21
- Steffen Maßberg · 1 shared paper, 2026 · strength 0.21
- Konstantin Stark · 1 shared paper, 2026 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.